Celgene management restructuring
Celgene Chairman and CEO John Jackson will step down as CEO effective May 1, 2006, but will continue serving as chairman of the board of directors. President and COO Sol Barer will assume the position of CEO, while senior VP and CFO Robert Hugin will take over Barer's current role. The biopharmaceutical company said it is actively seeking a new CFO and hopes to fill the position by May. The new management team will be responsible for overseeing the launch of Revlimid; the transition announcement coincided with FDA approval of Revlimid (lenalidomide) Dec. 27 for the treatment of blood cancer...
You may also be interested in...
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.
Execs On The Move: Medical Microinstruments Gets New CEO; Changes At iRhythm; Aethlon Makes A Promotion
Corindus Vascular Robotics CEO made a lateral move to Medical Microinstruments; iRhythm hires a new CEO, while the former CEO stays on as a director; Aethlon promotes a director to chief business officer; and more.